Medicare adds fourth drug compendium for Part B coverage
Executive Summary
Elsevier Gold Standard's Clinical Pharmacology is officially recognized as a valid reference for determining off-label coverage of cancer drugs under Medicare Part B. The decision completes CMS' review of compendia recognition requests received earlier this year. Of four compendia nominated, three have been officially recognized by the agency; the other two are Thomson Micromedex's DrugDex and the National Comprehensive Cancer Network Drugs & Biologics Compendium. They join the currently recognized compendium that is still in print - American Hospital Formulary Service-Drug Information - bringing to four the number of officially recognized compendia that now may be used for coverage decisions
You may also be interested in...
Off-Label Targeted Cancer Therapy Review Could Aid Compendia Evaluation
A CMS-sponsored review of the data available to support off-label use of targeted cancer therapies could help evaluate whether the drug compendia used by Medicare as the basis for determining Part B coverage for off-label cancer drugs incorporate the most current data
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.